ADMA Biologics (ADMA)
$16.02 3.7%
to add to portfolio
AI Score
-
Alternative
9 -
Fundamental
10 -
Technical
6
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on ADMA Biologics, AI stock picks, stock alerts and much more.
ADMA AI Stock Analysis
Financial Performance
ADMA Biologics has shown a strong financial performance with an upward trend in revenues, gross profit, and operating income. The company's revenue grew by 11.8% from the previous quarter and by 62.2% YoY, indicating strong sales growth. Gross profit also increased significantly by 93.1% YoY, suggesting improved cost management or pricing power. Operating income saw a massive increase of 178.5% YoY, which is indicative of efficient operations and profitability.
The EBITDA ratio at 0.35 suggests that the company is generating decent earnings before interest, tax, depreciation and amortization costs are considered.
Stock Price
The stock price currently trades at $18.44 which is above its 200-day moving average of $13.99 indicating bullish sentiment among investors in the long term despite a minor dip of -0.8% in the past month.The PE ratio stands at a high level of 68.30 suggesting that investors have high expectations for future earnings growth.
Alternative Data Signals
A slight decrease in web traffic could indicate less interest or awareness about ADMA Biologics' products or services but this isn't necessarily alarming as it's only down by -2%. Job postings decreased by -6.5% MoM and -35.1% YoY which may suggest slower expansion plans or cost-saving measures being implemented.
A positive business outlook reported by an estimated 66% of employees bodes well for morale and productivity within the company while social media followers on Twitter have increased over time reflecting growing public interest.
Conclusion
In conclusion, despite some mixed signals from alternative data, the strong financial performance and bullish long-term market sentiment make ADMA Biologics' stock a relatively attractive investment. The analysis is therefore leaning more towards being bullish.
Note: This AI Stock Analysis is based on data as of January 06. Our members can refresh and get access to an up-to-date AI stock analysis.
Sign up
ADMA Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of ADMA Biologics (ADMA), currently trading at $16.02, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About ADMA
-
ADMA Biologics, Inc.
-
Symbol
ADMA
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
3.8B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$22.78 0.5% |
6 |
 |
Inovio Pharmaceuticals INO |
$2.08 8.9% |
4 |
 |
Moderna MRNA |
$34.06 0.9% |
4 |
 |
Anavex Life Sciences AVXL |
$9.21 9.3% |
6 |
 |
BridgeBio Pharma BBIO |
$33.79 0.9% |
7 |
News
ADMA Alternative Data
News Mentions
Sign up to access
Twitter Followers
Sign up to access
LinkedIn Followers
Sign up to access
Job Postings
Sign up to access
LinkedIn Employees
Sign up to access
Web Traffic
Sign up to access
Business Outlook
Sign up to access
ADMA Financials
ADMA Key Metrics
-
Total Revenue
$119.8M
-
Net Income
$35.9M
-
Earnings per Share
$0.15
-
Free cash flow
$24.3M
-
EBITDA
$42.2M
-
EBITDA Ratio
0.352039
-
Total Assets
$390.6M
ADMA 2-year Revenue & Income
ADMA 2-year Free Cash Flow
ADMA Technicals
ADMA SMA
ADMA RSI
FAQ
What's the current price of ADMA Biologics (ADMA) Stock?
The price of an ADMA Biologics (ADMA) share is $16.02.
What's the market cap of ADMA Biologics?
The current market cap of ADMA Biologics is 3.8B.
Should I buy or sell ADMA?
Multiple alternative data signals suggest that ADMA Biologics stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.
Is ADMA Biologics a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in ADMA Biologics stock. The bullish indicators suggest that ADMA Biologics' growth prospects and market position may lead to a positive performance in the foreseeable future.
Is now a good time to buy ADMA Biologics (ADMA) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying ADMA Biologics stock, given the bullish outlook.
What are some stocks similar to ADMA Biologics (ADMA) that investors often compare it to?
ADMA Biologics (ADMA) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for ADMA Biologics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast ADMA Biologics' stock price to be around $18.24 in 2026. Starting from the current price of $16.02, this represents a 13.9% change in price, indicating a bullish outlook for the stock.
How to buy ADMA Biologics (ADMA) Stock?
ADMA Biologics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy ADMA Biologics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.